This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2021, there were approximately 1.8 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.
• Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.
• The approved drugs for systemic hypertension focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.
• The majority of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase II. Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, topical, and intravenous formulations.
• High-impact upcoming events for systemic hypertension drugs comprise topline Phase II trial results for CIN-107 and zilebesiran, as well as topline Phase III trial results for firibastat.
• The overall likelihood of approval of a Phase I systemic hypertension asset is 6.6%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 7.4 years from Phase I to approval, compared to 10.4 years in the overall cardiovascular space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for hypertension have been in the late phases of development, with 53% of trials in Phase III–IV and 47% in Phase I–II.
• The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.
• Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 323 trials. Novartis also leads industry sponsors with by far the highest overall number of clinical trials for hypertension.